Leinco Technologies

Anti-Human CD62E (E-Selectin) - Purified

Product Code:
 
LEI-C674
Product Group:
 
Primary Antibodies
Host Type:
 
Mouse
Antibody Isotype:
 
IgG1
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
1.2B6
Regulatory Status:
 
RUO
Target Species:
 
Human
Applications:
  • Flow Cytometry
  • Immunoprecipitation (IP)
  • Western Blot (WB)
Shipping:
 
Ambient
Storage:
 
For use within 1 month of purchase store at 2-8°C. For long term storage freeze working aliquots at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-C674-0.1mg0.1 mg£625.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Related Products
  • Show All

Further Information

Concentration:
0.1 mg/ml
Conjugate/Tag/Label:
Purified
Format:
This purified monoclonal antibody is formulated in phosphate buffered saline (PBS), 1 mg/ml BSA and 10 mM sodium azide as a preservative.
Formulation:
This purified monoclonal antibody is formulated in phosphate buffered saline (PBS), 1 mg/ml BSA and 10 mM sodium azide as a preservative.
Immunogen:
TNF-Activated Human Umbilical Vein Endothelial Cells
Long Description:
E-selectin, also known as CD62E is an inducible leukocyte adhesion glycoprotein specifically expressed by endothelial cells.1 E-selectin helps initiate recruitment of circulating leukocytes to cutaneous, bone and inflamed tissues.2 E-selectin is found in inflammatory skin lesions in psoriasis, contact dermatitis, and delayed- type hypersensitivity, in arthritic joints, and in heart and renal allografts undergoing rejection.3 E-selectin-targeting antibody drug conjugate has potential as a prostate cancer therapy.4
NCBI Gene:
6401
Target:
CD62E

References

1. Milstone D et al. (2004) PNAS 101: 8005 2. Dimitroff CJ et al. (2009) J Visualized Experiments 3. Takako Hirata et al. (2005) J Immunol. 175: 8042 4. Ramakrishnan Vanitha et al. (2003) Cancer Res. 63: 6387